medigraphic.com
ISSN 1561-3194 (Electronic)

2016, Number 4

<< Back Next >>

Rev Ciencias Médicas 2016; 20 (4)

Influence on the evolution of the prognostic factors during the relapse of epithelial ovarian cancer

Labrador AM, Sánchez AY, Quintero PW, Gener RY, Labrador AD

Language: Spanish
References: 15
Page: 434-441
PDF size: 288.07 Kb.


ABSTRACT

Introduction: epithelial ovarian cancer is considered the most lethal gynecological neoplasm in the Western Hemisphere, due in part to the high rate of relapses in the first 2 to 5 years of their initial diagnosis.
Objective: to evaluate the influence of the evolution of prognostic factors on the relapses of epithelial ovarian cancer in patients attending the Tercer Congreso Provincial Cancer Center during 2010-2014.
Method: a descriptive, analytical, retro-prospective, longitudinal epidemiological research was carried out, with a sample of 62 patients diagnosed with epithelial ovarian cancer. Kaplan-Meier Survival Curves and Logrank Tests were applied.
Results: disease-free survival was 59.7%. The factors that influenced on the relapse of patients were the stages of the disease, residual tumor size and sensitivity to platinum salts (p ‹ 0.05). The histological characteristics did not influence on the evolution of the patients (p › 0.05).
Conclusions: Prognostic factors for relapse of epithelial ovarian cancer in Pinar del Rio are: clinical stage, residual tumor size and sensitivity to platinum salts.


REFERENCES

  1. Rojas S, Bravo E, Alonso C, Parry S. Videotoracoscopía en cáncer de ovario avanzado con sospecha de compromiso torácico. RevChilObstetGinecol [Internet]. 2012 [citado 9 Mar 2014]; 77(3): [aprox. 4 p.]. Disponible en: http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0717 -75262012000300004&lang=pt

  2. Acosta Peñaloza JA. Carcinoma epitelial de ovario. Hacia los equipos multidisciplinarios. Rev Coloma Cancerol [Internet]. 2013 [citado 4 Feb 2015]; 17(4): [aprox. 5 p.]. Disponible en: http://www.scielo.org.co/scielo.php?script=sci_arttext&pid=S0123-90152013000400001&lang=pt

  3. Lien Tamayo T, Santana Iglesias O, Fiallo Carvajal L. Tumor de Krukenberg. Rev Cubana ObstetGinecol [Internet]. 2014 Mar [citado 4 feb 2015]; 40(1): [aprox. 8 p.]. Disponible en:http://scieloprueba.sld.cu/scielo.php?script=sci_arttext&pid=S0138 -600X2014000100011&lng=es&nrm=iso

  4. Valladares M, Corsini G, Romero C. Asociación entre obesidad y cáncer de ovario. RevMéd Chile [Internet]. 2014 [citado 4 Feb 2015]; 142(5): [aprox. 5 p.]. Disponible en: http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034 -98872014000500007&lang=pt

  5. Manual de Oncología Clínica del Brasil. Hospital San José. 2013; 247-264. Disponible en: http://www.mocbrail.com

  6. Platelet to lymphocyte ratio as a prognostic factor for epithelial ovarian cancer. Raungkaewmanee S, Tangjitgamol S, Manusirivithaya S, Srijaipracharoen S, Thavaramara T. J GynecolOncol. 2012 Oct; 23(4):265-73.

  7. Villegas Valverde CA, Arango Prado del MC. Participación de los linfocitos T reguladores en el cáncer de ovario. Rev Cubana ObstetGinecol [Internet]. 2013 Mar [citado 4 Feb 2015]; 39(1): [aprox. 8 p.]. Disponible en: http://scieloprueba.sld.cu/scielo.php?script=sci_arttext&pid=S0138 -600X2013000100004&lng=es&nrm=iso

  8. NCCN Guidelines Version 1.2015. Epithelian Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer. Disponible en: http://www.nccn.org/patients

  9. Serum levels of macrophage migration-inhibitory factor (MIF) have diagnostic, predictive and prognostic roles in epithelial ovarian cancer patients.Tumor Markers, Tumor Targeting and Translational Cancer Research 2013 35:1438. [citado 26 Jun 2015] Disponible en: http://health.springer.com/article/10.1007/s13277-013-1438-z/fulltext.html

  10. Bian C , Yao K , Li L , Yi T , Zhao X . Primary debulking surgery vs. neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancer. ArchGynecolObstet. 2015 Jul 22. [consultado 11 de septiembre 2015]http://www.ncbi.nlm.nih.gov/pubmed/26198168

  11. Nowak-Markwitz E , Spaczynski M. Ovarian cancer—modern approach to its origin and histogenesis. Ginekol Pol.2012 Jun;83(6):454-7. [consultado 11 de septiembre 2015] http://www.ncbi.nlm.nih.gov/pubmed/22880466

  12. Lozneanu L , Avadanei R , Cîmpean AM , Giusca SE , Amalinei C , Caruntu ID . Relationship between the proangiogenic role of EG-VEGF, clinicopathological characteristics and survival in tumoral ovary. RevMedChirSocMedNatIasi. 2015 Apr-Jun;119(2):461-5. [consultado 11 de septiembre 2015] http://www.ncbi.nlm.nih.gov/pubmed/26204653

  13. Hu L , Cong L . Fibroblast growth factor 19 is correlated with an unfavorable prognosis and promotes progression by activating fibroblast growth factor receptor 4 in advanced-stage serous ovarian cancer. Oncol Rep. 2015 Aug 20. doi: 10.3892/or.2015.4212. [consultado 11 de septiembre 2015] http://www.ncbi.nlm.nih.gov/pubmed/26323668

  14. YulanRen , Rong Jiang , Sheng Yin , Chao You , Dongli Liu , Xi Cheng et al. Radical surgery versus standard surgery for primary cytoreduction of bulky stage IIIC and IV ovarian cancer: an observational study. BMC Cancer. 2015; 15: 583. Published online 2015 Aug 13. doi: 10.1186/s12885-015-1525-1 PMCID: PMC4535562. [consultado 11 de septiembre 2015] http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4535562/

  15. McEvoy LM , O'Toole SA , Spillane CD , Martin CM , Gallagher MF , Stordal B et al. Identifying novel hypoxia-associated markers of chemoresistance in ovarian cancer. BMC Cancer. 2015 Jul 25;15:547. doi: 10.1186/s12885-015-1539-8. [consultado 11 de septiembre 2015]http://www.ncbi.nlm.nih.gov/pubmed/26205780




2020     |     www.medigraphic.com